CY1119851T1 - Μεθοδος για τη θεραπεια σηψης σε ασθενεις με επιπεδα αλβουμινης, χοληστερολης και hdl πανω απο τα ελαχιστα ορια - Google Patents

Μεθοδος για τη θεραπεια σηψης σε ασθενεις με επιπεδα αλβουμινης, χοληστερολης και hdl πανω απο τα ελαχιστα ορια

Info

Publication number
CY1119851T1
CY1119851T1 CY20181100077T CY181100077T CY1119851T1 CY 1119851 T1 CY1119851 T1 CY 1119851T1 CY 20181100077 T CY20181100077 T CY 20181100077T CY 181100077 T CY181100077 T CY 181100077T CY 1119851 T1 CY1119851 T1 CY 1119851T1
Authority
CY
Cyprus
Prior art keywords
cholesterol
albumin
patients
treatment
hdl levels
Prior art date
Application number
CY20181100077T
Other languages
English (en)
Inventor
Daniel M. Levine
Thomas S. Parker
Bruce R. Gordon
Stuart D. Saal
Original Assignee
Sepsicure L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepsicure L.L.C. filed Critical Sepsicure L.L.C.
Publication of CY1119851T1 publication Critical patent/CY1119851T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μια μέθοδο για τη θεραπεία της σήψης σε υποκείμενα που παρουσιάζουν επίπεδα ορού αλβουμίνης, και ένα από τα επίπεδα ολικής χοληστερόλης ή HDL, πάνω από τις ελάχιστες οριακές τιμές. Η μέθοδος περιλαμβάνει ενδοφλέβια χορήγηση ενός γαλακτώματος, το οποίο περιέχει ένα φωσφολιπίδιο, ένα ουδέτερο λιπίδιο, και ένα χολικό άλας.
CY20181100077T 2012-12-18 2018-01-22 Μεθοδος για τη θεραπεια σηψης σε ασθενεις με επιπεδα αλβουμινης, χοληστερολης και hdl πανω απο τα ελαχιστα ορια CY1119851T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/718,246 US9023833B2 (en) 2012-12-18 2012-12-18 Method for treating sepsis in patients with albumin, cholesterol and HDL levels above minimum thresholds
PCT/US2013/062629 WO2014099089A1 (en) 2012-12-18 2013-09-30 Method for treating sepsis in patients with albumin, cholesterol and hdl levels above minimum thresholds

Publications (1)

Publication Number Publication Date
CY1119851T1 true CY1119851T1 (el) 2018-06-27

Family

ID=50931609

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100077T CY1119851T1 (el) 2012-12-18 2018-01-22 Μεθοδος για τη θεραπεια σηψης σε ασθενεις με επιπεδα αλβουμινης, χοληστερολης και hdl πανω απο τα ελαχιστα ορια

Country Status (26)

Country Link
US (1) US9023833B2 (el)
EP (1) EP2934152B1 (el)
JP (1) JP5963973B2 (el)
KR (1) KR20150069023A (el)
CN (1) CN104869830B (el)
AP (1) AP2015008443A0 (el)
AU (1) AU2013364214B2 (el)
CA (1) CA2892764C (el)
CY (1) CY1119851T1 (el)
DK (1) DK2934152T3 (el)
ES (1) ES2658418T3 (el)
HK (1) HK1214084A1 (el)
HR (1) HRP20180185T8 (el)
HU (1) HUE036041T2 (el)
IL (1) IL239060A0 (el)
LT (1) LT2934152T (el)
MX (1) MX362246B (el)
NO (1) NO3013861T3 (el)
NZ (1) NZ707550A (el)
PL (1) PL2934152T3 (el)
PT (1) PT2934152T (el)
RS (1) RS56840B1 (el)
RU (1) RU2571688C1 (el)
SI (1) SI2934152T1 (el)
UA (1) UA113231C2 (el)
WO (1) WO2014099089A1 (el)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5587366A (en) 1992-08-12 1996-12-24 The Rogosin Institute Compositions useful in prophylaxis and therapy of endotoxin related conditions
US6740487B1 (en) * 1999-06-10 2004-05-25 University Of Iowa Research Foundation Variant TLR4 nucleic acid and uses thereof
US7273847B2 (en) * 2000-06-30 2007-09-25 Mccormack Jr Francis X Peptides with antioxidant and antimicrobial properties
JP4683740B2 (ja) * 2001-02-15 2011-05-18 明治乳業株式会社 炎症に伴う症状の軽減剤
NZ565590A (en) 2005-08-29 2010-07-30 Sepsicure L L C Use of a protein free composition comprising cholinic acid and a phosphosphlipid for the treatment or prevention of conditions caused by gram-positive bacteria
WO2011050126A1 (en) * 2009-10-21 2011-04-28 University Of Medicine And Dentistry Of New Jersey Method for treating sepsis or septic shock

Also Published As

Publication number Publication date
ES2658418T3 (es) 2018-03-09
CN104869830A (zh) 2015-08-26
US9023833B2 (en) 2015-05-05
EP2934152A1 (en) 2015-10-28
HRP20180185T1 (hr) 2018-03-09
SI2934152T1 (en) 2018-05-31
KR20150069023A (ko) 2015-06-22
WO2014099089A1 (en) 2014-06-26
AU2013364214A1 (en) 2015-05-21
LT2934152T (lt) 2018-02-26
DK2934152T3 (en) 2018-01-15
HK1214084A1 (zh) 2016-07-22
AU2013364214B2 (en) 2015-11-05
HUE036041T2 (hu) 2018-06-28
IL239060A0 (en) 2015-07-30
CA2892764C (en) 2015-11-24
JP2016505575A (ja) 2016-02-25
AP2015008443A0 (en) 2015-05-31
US20140171391A1 (en) 2014-06-19
NZ707550A (en) 2016-01-29
UA113231C2 (xx) 2016-12-26
PT2934152T (pt) 2018-02-22
HRP20180185T8 (hr) 2018-11-16
CN104869830B (zh) 2018-03-09
RU2571688C1 (ru) 2015-12-20
PL2934152T3 (pl) 2018-07-31
NO3013861T3 (el) 2018-04-28
JP5963973B2 (ja) 2016-08-03
RS56840B1 (sr) 2018-04-30
EP2934152A4 (en) 2016-11-16
EP2934152B1 (en) 2017-11-08
CA2892764A1 (en) 2014-06-26
MX362246B (es) 2019-01-09
MX2015007828A (es) 2015-08-20

Similar Documents

Publication Publication Date Title
CY1123693T1 (el) Παραγοντες rnai, συνθεσεις και μεθοδοι χρησης αυτων για τη θεραπευτικη αγωγη σχετιζομενων με τρανσθυρετινη (ttr) ασθενειων
CY1120195T1 (el) Συνθεσεις irna toy pcsk9 και μεθοδοι χρησης αυτων
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1121153T1 (el) Παραγωγα εξενδινης-4 ως διπλοι glp1/gιp- ή τριγωνικοι αγωνιστες glp1/gιp/γλυκαγονης
CY1123858T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CY1120419T1 (el) Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμου
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
EA201592107A1 (ru) Доставка иммунодепрессантов, имеющих определенный фармакодинамически эффективный период, и антигена для индукции иммунной толерантности
BR112014026072A2 (pt) método para medir atenção
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
CY1122185T1 (el) Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
UY33575A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201590388A1 (ru) Способы лечения таупатии
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES